An observational study of non-small cell lung cancer in 270 patients with metastatic non-small cell lung cancer who received at least one treatment with anti-PD-L1 or anti-PD-1 antibodies showed that the efficacy of anti-PD-1 and anti-PD-L1 antibodies was associated with the pathogenesis of irAE.In this study, 89.3% of the patients received anti-PD-1 antibody treatment and the rest received anti-PD-L1 antibody treatment. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.